Gene · 3357
HTR2B: 5-hydroxytryptamine receptor 2B
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HTR2B: 5-hydroxytryptamine receptor 2B. Genes, record 3357. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3357
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P41595 | 5-hydroxytryptamine receptor 2B | 481 | 12 | Ensembl, GeneID, HGNC |
Source UniProt
Patents48
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026062654 A | 2026-04-10 | 49 | P41595 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 35760 | P41595 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1290 | P41595 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 71 | P41595 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2006 | P41595 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2006 | P41595 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1290 | P41595 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 398 | P41595 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 71 | P41595 | Espacenet |
| JP 2025500034 A | 2025-01-07 | 3 | P41595 | Espacenet |
1 to 10 of 48
See all 48 patentsDrugs16
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMISULPRIDE | CHEMBL243712 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
| CLOTHIAPINE | CHEMBL304902 | Serotonin 2 (5-HT2) receptor antagonist | ANTAGONIST | ChEMBL |
| DEXFENFLURAMINE | CHEMBL248702 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| DEXFENFLURAMINE HYDROCHLORIDE | CHEMBL1887891 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| METHYLERGONOVINE | CHEMBL1201356 | Serotonin 2b (5-HT2b) receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| METHYLERGONOVINE MALEATE | CHEMBL1200843 | Serotonin 2b (5-HT2b) receptor partial agonist | PARTIAL AGONIST | ChEMBL |
| METHYSERGIDE | CHEMBL1065 | Serotonin 2b (5-HT2b) receptor antagonist | ANTAGONIST | ChEMBL |
| METHYSERGIDE MALEATE | CHEMBL1200938 | Serotonin 2b (5-HT2b) receptor antagonist | ANTAGONIST | ChEMBL |
| MINAPRINE | CHEMBL278819 | Serotonin 2 (5-HT2) receptor antagonist | ANTAGONIST | ChEMBL |
| MINAPRINE HYDROCHLORIDE | CHEMBL1364551 | Serotonin 2 (5-HT2) receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 16
See all 16 drugsTrials45
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07152184 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06887621 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06585540 | AMISULPRIDE | PHASE3 | ClinicalTrials.gov | |
| NCT06581302 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT06040944 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05956600 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05347199 | AMISULPRIDE | PHASE1 | ClinicalTrials.gov | |
| NCT04954365 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT04533724 | AMISULPRIDE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT04529226 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 45
See all 45 trialsNIH grants1,397
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HTR2B papers | Newest fiscal year |
|---|---|---|---|
| R01MH112205 | Molecular Details of Psychoactive Drug Actions | 13 | 2025 |
| ZIAAA000301 | Integrative genetics of behavior with high throughput technologies | 13 | 2025 |
| ZIADA000522 | Preclinical medication development for stimulant use disorder | 9 | 2025 |
| R35GM122481 | Development and Testing of New Computational Methods for Ligand Discovery and Mechanism | 8 | 2025 |
| R37DA045657 | Mechanistic insights into LSD actions at 5-HT2A serotonin receptors | 7 | 2025 |
| ZIADK031126 | Computer Modeling of G Protein-Coupled Receptors | 7 | 2025 |
| ZIADK031117 | Development of Drugs Acting at Adenosine Receptors | 6 | 2025 |
| ZIAMH002793 | PET Radiopharmaceutical Sciences | 5 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 4 | 2025 |
| P30EY014801 | Miami Center for Vision Research | 4 | 2025 |
1 to 10 of 1,397Source NIH's project files
See all 1,397 nih grantsPapers2,210
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Deciphering the allosteric landscape of 5-HT2 receptors: integrated molecular dynamics and fragment molecular orbital analyses of activation mechanisms. | Pharmacol Rep | 2026 | 42789242 | PubTator, text mining | PubMed |
| Mechanisms of Serotonergic Modulation of Glial Cell Functions in the Recovery Period After Spinal Cord Injury. | Cells | 2026 | 42782768 | PubTator, text mining | PubMed |
| Integrative multi-omics analysis prioritizes compartment-specific candidate targets of gut microbiota metabolites in diabetic kidney disease. | Front Immunol | 2026 | 42756821 | PubTator, text mining | PubMed |
| Pharmacological Activity of Motugivatrep, a Novel Antagonist of Transient Receptor Potential Cation Channel Subfamily V Member 1. | Biol Pharm Bull | 2026 | 42749621 | PubTator, text mining | PubMed |
| Propofol alleviates OGD/R-induced cerebral ischemia-reperfusion injury-related neuronal injury by regulating NEDD4L-mediated ubiquitination of HTR2B. | Biochem Biophys Res Commun | 2026 | 42748874 | PubTator, text mining | PubMed |
| Can docking-score differences support 5-HT2A/5-HT2B subtype-selectivity decisions? An audited paired benchmark. | In Silico Pharmacol | 2026 | 42707358 | PubTator, text mining | PubMed |
| Mechanosensing channels PIEZO1 and PIEZO2 regulate mitral valve serotonin-mediated homeostasis and pathophysiology. | Cardiovasc Res | 2026 | 42687771 | PubTator, text mining | PubMed |
| Cardiovascular safety of psilocybin in psychiatric practice: a narrative review. | Eur J Clin Pharmacol | 2026 | 42538465 | PubTator, text mining | PubMed |
| Perioperative Esmolol Is Associated with Early Opioid Sparing in Patients with Ischemic Heart Disease: Evidence from a Retrospective Cohort and an Incisional Pain Rat Model. | Curr Med Sci | 2026 | 42490018 | PubTator, text mining | PubMed |
| Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development. | Epilepsia | 2026 | 42470359 | PubTator, text mining | PubMed |
1 to 10 of 2,210
See all 2,210 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3357
GET https://conductscience.org/api/genes/v1/3357/patents?page=2